1. Scrip
  2. >>Business
  3. >>Strategy

Five Prime Enters Transition Phase; Multiple Trials Planned In Next 12 Months

 
• By Lucie Ellis-Taitt

Five Prime, in partnership with immunotherapy giant Bristol-Myers Squibb, will launch several pivotal trials in the next 12 months for its lead compound cabiralizumab – both in combination with Opdivo in cancer and as a monotherapy in orphan disease PVNS.

Butterfly
R&D progress has pushed Five Prime into a 'transition phase,' says CEO • Source: Shutterstock

Five Prime Therapeutics Inc. has set itself ambitious targets for the next 12 months that will see the company launch trials for a novel immunotherapy and chemotherapy combination in first-line gastric cancer and for its lead compound cabiralizumab in the joint tumor disease, pigmented villonodular synovitis (PVNS).

In the coming months, the San Francisco-based biotech will also progress cabiralizumab in several cancer indications in combination with Bristol-Myers Squibb Co

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

More from Business

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.